Women's Behavioral Healthcare, Western Psychiatric Institute and Clinic, 3811 O'Hara St., Pittsburgh, PA 15213, USA.
Psychiatr Serv. 2011 Feb;62(2):218-20. doi: 10.1176/ps.62.2.pss6202_0218.
Valproate is associated with polycystic ovary syndrome as well as congenital malformations and developmental delays of infants who were prenatally exposed. The frequency of valproate use for mental health conditions among women of childbearing age was determined.
Using New York State Medicaid claims for persons with psychiatric disorders, 40,526 individuals with active prescriptions for mood stabilizers (non-antipsychotic) on May 1, 2009, were identified. Chi square tests were used to compare valproate use among women of childbearing age with similarly aged men and older women.
Valproate was the most commonly prescribed agent for young women (23.4%). Men were more likely than women, and older women more likely than younger women, to take valproate.
Over 20% of childbearing-aged women receiving mood stabilizers were treated with valproate, although increasing data on the reproductive toxicity of this agent compel consideration of other non-antipsychotic mood stabilizers as first-line choices.
丙戊酸盐与多囊卵巢综合征以及产前暴露的婴儿先天畸形和发育迟缓有关。本研究旨在确定育龄妇女使用丙戊酸盐治疗精神健康状况的频率。
利用纽约州医疗补助计划（Medicaid）针对精神疾病患者的索赔数据，于 2009 年 5 月 1 日确定了 40526 名正在使用心境稳定剂（非抗精神病药）的患者。采用卡方检验比较育龄妇女与同龄男性和老年女性使用丙戊酸盐的情况。
丙戊酸盐是年轻女性最常开的药物（23.4%）。男性比女性更有可能使用丙戊酸盐，老年女性比年轻女性更有可能使用丙戊酸盐。
尽管越来越多的数据表明该药物具有生殖毒性，但仍有超过 20%的育龄妇女接受心境稳定剂治疗时使用丙戊酸盐，因此应考虑将其他非抗精神病药的心境稳定剂作为一线选择。
